Inocras is dedicated to revolutionizing patient diagnostics and treatment by harnessing the full potential of whole-genome data and advanced algorithms. Specializing in cancer and rare diseases, our AI-powered bioinformatics platform transforms genomic data into actionable insights, enabling personalized care based on each individual’s unique genetic makeup. In addition to our clinical offerings, Inocras provides comprehensive research services, partnering with clients to tackle complex genomics challenges. From whole genome sequencing in our CAP/CLIA-certified San Diego lab to leveraging our proprietary bioinformatics pipeline, we deliver unparalleled insights into the human genome to empower innovation and discovery. | We are Inocras, a precision health platform company providing whole genome insights to enable personalized care in cancer and rare diseases. We have a full suite of cancer diagnostic solutions (cancer diagnostics, screening, and recurrence monitoring), rare disease and personal genomics solutions that have launched in USA/Korea/Hong Kong. Our CLIA/CAP certified and full service lab is located in San Diego where we sequence a variety of specimen types. In addition, we also provide genetic counseling, clinical trial matching, and additional R&D support services (e.g., sequencing, bioinformatics, etc).
Illumina
At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. The innovative products that we provide are helping drive advancements in a multiomic understanding of cellular functions, combining transcriptomics, epigenetics, and proteomics. Multiomics profiling studies enable a more comprehensive understanding of development, cellular response, and disease, fueling the discovery of novel drug targets and biomarkers. The progress our customers have made and what lies ahead inspire us to push the boundaries of what is possible so we can create the next generation of genomics solutions. | At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays provide accurate, high-throughput genotyping for a range of applications. The innovative products that we provide have already helped researchers make breakthroughs in many biological areas, including oncology, reproductive health, genetic disease, precision medicine, agriculture, microbiology, and beyond. The progress we see inspires us to push the boundaries of what is possible so we can create the next generation of genomics solutions. | At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
IDeA National Resource for Quantitative Proteomics
The mission of the IDeA National Resource for Quantitative Proteomics are to provide unmatched and most cost-effective access to state-of-the-art quantitative proteomics platforms and education, outreach, and training opportunities that will increase the capacity of NIH-funded investigators, and others in academic laboratories across the United States, to perform cutting-edge biomedical research.
GenScript USA Inc
GenScript USA Inc is a pioneering biotechnology company dedicated to advancing life science research, drug discovery, and development through innovative solutions. With a relentless commitment to excellence, GenScript has become a global leader in providing a comprehensive portfolio of services and products that empower scientists and researchers to push the boundaries of science and medicine. Our expertise spans a wide spectrum of disciplines, including gene synthesis, IVT mRNA, peptides, gene editing, protein engineering, antibody development, cell line generation, and molecular biology reagents. We pride ourselves on our ability to accelerate research and development timelines by delivering high-quality, reliable tools and services that fuel breakthroughs in various scientific fields. Learn more about us at www.genscript.com | GenScript USA Inc is the world’s leading technology and service provider of life science R&D and manufacturing. Built upon solid gene synthesis technology, GenScript offers comprehensive services supporting gene and cell therapy development. From Gene Synthesis, CRISPR sgRNA, Non-viral Payload (ssDNA, dsDNA), mRNA, Oligo, Peptide synthesis, to protein, antibody and virus production. GenScript also offers CDMO platforms supporting GCT with cGMP CRISPR sgRNA/NVPs, plasmids, and virus. We are dedicated to providing reliable, high-quality, and innovative reagents and instruments with superior customer service to enable success across a wide variety of existing and emerging life science research and development areas. We will help you Make Research Easy.
Genomic Testing Cooperative
Genomic Testing Cooperative (GTC) offers sequencing and IHC services for research projects and clinical trials. This includes all forms of sequencing and NGS applications including DNA, RNA, cfDNA and cfRNA. Projects are performed in our CAP and CLIA accredited laboratory. Our Co-Op business model has an ecosystem of labs with mirrored testing capabilities globally. GTC can support retrospective, prospective and CDx projects.
Genomeditech
Genomeditech (Shanghai) Co., Ltd. was established in 2011 and is a high-tech enterprise specializing in the research and development of cutting-edge biotechnology. We have established technology platforms in molecular biology, cell biology, virus packaging, cell line construction, reporter genes, antibody expression, protein expression, and IVD. In 2020, Genomeditech launched a sub-brand, DDXCELL, focusing on biopharmaceutical development by providing efficient R&D tools and solutions. As of now, the company has developed nearly 400 popular drug targets and over 1,000 available monoclonal cell lines. These targets include tumor-associated antigens (TAA), immune checkpoints, cytokines, kinases, and more. Additionally, a large collection of proteins, antibodies, and reagents is available. To support vaccine development, Genomeditech has also introduced a series of ready-to-use pseudoviruses and receptor cells, covering products for COVID-19, influenza, HPV, and other pathogens.
GENEWIZ from Azenta Life Sciences
Are you looking to learn more about for the latest advancements in NGS and Gene Synthesis while you’re at AACR? Make sure stopping by GENEWIZ booth 3422 is on the top of your list. Learn about game changing updates to our NGS and Gene Synthesis portfolios, play Spin-to-Win, and chat with our experts for answers to your pressing Preclinical and Clinical services questions. And then stop by our posters to connect with our experts. GENEWIZ from Azenta Life Sciences is a leading global genomics service company and trusted provider for Sanger sequencing, next generation sequencing, gene synthesis, molecular biology, bioinformatics, and GLP regulatory services. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. Our customers at top-tier pharmaceutical, biotechnology, and academic institutions, as well as cutting-edge start-ups, rely on our proprietary technologies for consistent, reliable, high-quality data, even on the most difficult projects. A full-service provider, GENEWIZ provides Sanger DNA sequencing, gene synthesis, molecular biology, high throughput/next generation sequencing, bioinformatics, and GLP regulatory services.
GeneReach Biotechnology Corporation
GeneReach Biotechnology Corporation, headquartered in Taiwan, is dedicated to bringing the innovation to global health management. By developing, manufacturing and marketing products for applied nucleic acid detection technology, we offer pathogen detection platforms, including equipment and reagents, to multiple industries. The applications of our products include aquaculture, agriculture, food, companion animal, livestock and human health industries. Our products are manufactured in compliance with the requirements of Quality Management System (QMS) in addition to ISO 13485. Developing the high performance and user friendly products is the major driving force of our research and development team. Based on this philosophy, GeneReach Biotechnology Corporation manufactures products which are reliable, affordable and easy to perform. Our goal is to provide the best detection products and service worldwide and down to the extreme of Point of Care market.
GeneCker Co., Ltd.
GeneCker is a biotechnology company specializing in ultra-precision CRISPR technology and the MUTE-Seq® platform—an ultrasensitive liquid-biopsy NGS solution. From research and development to kit manufacturing, we provide an end-to-end service for advanced cancer genomics. Our flagship CRISPincette MultiCancer kit incorporates both our patented MUTE-Seq® and CRISPR gcCas9 technologies to enrich variant-containing DNA fragments for accurate multi-cancer risk assessment. With operations in Korea, China, and other global markets, GeneCker delivers solutions for Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) monitoring at ~20× higher analytical precision and one-tenth the per-sample cost compared to conventional UMI-based NGS.
GeneCopoeia
GeneCopoeia has manufactured and released into the market the largest number of human full length protein coding ORF cDNA clones in multiple sets of vector systems with various features which make these clones suitable for a variety of functional assays, protein expression and easy purification in many cell types as well as cell free transcription and translation coupling systems, and large-scale functional genomics and proteomics studies.